Pharsight

Drugs that contain Ubrogepant

1. Ubrelvy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9499545 ABBVIE INC Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(7 years from now)

US8754096 ABBVIE INC Piperidinone carboxamide azaindane CGRP receptor antagonists
Jul, 2032

(8 years from now)

US8912210 ABBVIE INC Piperidinone carboxamide azaindane CGRP receptor antagonists
Dec, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9833448 ABBVIE INC Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(7 years from now)

US10117836 ABBVIE INC Tablet formulation for CGRP active compounds
Jan, 2035

(10 years from now)

US11717515 ABBVIE INC Treatment of migraine
Dec, 2041

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 23, 2024

NCE-1 date: 2023-12-24

Market Authorisation Date: 23 December, 2019

Treatment: Acute treatment of migraine with or without aura in adults; Acute treatment of migraine with or without aura in a patient with severe hepatic impairment; Acute treatment of migraine with headache, wit...

Dosage: TABLET;ORAL

More Information on Dosage

UBRELVY family patents

Family Patents

2. Ubrelvy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11857542 ABBVIE Treatment of migraine
Dec, 2041

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 23, 2024

NCE-1 date: 2023-12-24

Market Authorisation Date: 23 December, 2019

Treatment: Acute treatment of migraine with or without aura in a patient with severe renal impairment

Dosage: TABLET;ORAL

More Information on Dosage

UBRELVY family patents

Family Patents